Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Inclusion Criteria:

Randomized in the parent study, PCYC-1115-CA
Informed consent for Study PCYC-1116-CA
IRC-confirmed PD in the parent study PCYC-1115-CA or closure of the parent study

Exclusion Criteria:

Disease progression involving the central nervous system (CNS) or transformation to another histology
Intervening chemotherapy, immunotherapy, or investigational agent specifically to treat CLL if administered before date of IRC confirmed progressive disease
In the 4 weeks before dosing: radiation therapy, major surgery, or receipt of an investigational drug
Requirement for treatment with a strong CYP3A inhibitor
Uncontrolled systemic infection or requirement for IV antibiotics
Noncompliance on the parent study(PCYC-1115-CA)